Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board
September 17 2018 - 1:00AM
Press Release
17 September 2018
Immunicum AB (publ) Announces Appointment of Pawel Kalinski and
Inge Marie Svane to Scientific Advisory Board
Immunicum AB
(publ; IMMU.ST) announced today the appointment of leading oncology
experts to its Scientific Advisory Board with the addition of Pawel
Kalinski, MD, PhD, Vice Chair for Translational Research within the
Department of Medicine at Roswell Park Comprehensive Cancer Center,
and Inge Marie Svane, MD, PhD, Professor, Head of the Clinical
Cancer Research programme, Faculty of Health Sciences, University
of Copenhagen, Director, Centre for Cancer Immunotherapy (CCIT),
and consultant in Oncology, Herlev University Hospital. Both
Scientific Advisory Board members will serve as a strategic
resource to Immunicum as the company continues to advance the
clinical development of its lead product, ilixadencel.
"We are honored to have such
highly specialized experts in the field of immuno-oncology and cell
therapy join our Scientific Advisory Board and provide added
guidance on our clinical strategy," said Peter Suenaert, MD, PhD,
Chief Medical Officer of Immunicum. "We look forward to
collaborating with Pawel and Inge Marie as we continue to advance
the development of ilixadencel with the goal for it to be included
as a key component in future combination treatments for solid
tumors."
"Having developed multiple
investigator-sponsored INDs that cover dendritic cell therapies and
different forms of modulation of tumor microenvironments, I am
pleased to contribute my expertise as Immunicum seeks to harness
and apply the therapeutic potential of pro-inflammatory allogeneic
dendritic cells in patients with cancer," said Pawel Kalinski, who
is also Director of Cancer Vaccine and Dendritic Cell Therapies
within Roswell Park's Center for Immunotherapy.
"Immunicum has developed a very
unique and promising approach that stands out in the expanding
field of immuno-oncology combination therapies and I am impressed
with the clinical data the company has generated so far. Having had
the experience of developing a range of immunotherapeutic
strategies for a broad spectrum of cancer indications and advancing
them through Phase I to III clinical trials, I am eager to support
Immunicum's Scientific Advisory Board in actualizing the full,
fundamental potential in the company's lead product candidate and
pipeline," added Inge Marie Svane.
Pawel Kalinski is a distinguished
MD/PhD researcher with over 30 years of experience in the field of
tumor immunology. Dr. Kalinski's research focuses on cell therapies
and the manipulation of tumor microenvironments with a strong focus
on the biology of dendritic cells, T cells and tumor
microenvironment-associated myeloid cells. Currently, Pawel holds
the positions of Vice Chair for Translational Research, Department
of Medicine; Director of Cancer Vaccine and Dendritic Cell
Therapies, Center for Immunotherapy; Professor of Oncology; and
Co-Leader, Tumor Immunology & Immunotherapy (TII) CCSG Program,
at Roswell Park Comprehensive Cancer Center in Buffalo, NY, USA.
His research has been featured in over 120 international
publications. Dr. Kalinski is also a member of several prestigious
organizations including the Society for Immunotherapy of Cancer,
American Association for Cancer Research, American Society for
Clinical Investigation and the American Association of
Immunologists and is a member of the editorial board of leading
publications in the immuno-oncology field such as OncoImmunology and Journal for
Immunotherapy of Cancer.
Inge Marie Svane, MD, PhD, joins
Immunicum's Scientific Advisory Board with 25 years of research
experience in cancer immunology and immunotherapy. With her focus
of expertise on T cell based adoptive cell therapy and other
cellular therapies, cancer vaccines and immune regulation, she has
greatly contributed to the field of cancer immunotherapy. Since
2001 she has initiated more than 20 Phase I and II
immunotherapeutic trials as sponsor or principle investigator and
has served as investigator and co-investigator on numerous
international clinical trials in collaboration with the
pharmaceutical industry, primarily within the area of cancer
immunotherapy. Dr. Svane also led the establishment and currently
serves as Director of the Centre for Cancer Immunotherapy (CCIT),
Herlev University Hospital at the University of Copenhagen. Inge
Marie has served as Chair of the European Society for Medical
Oncology (ESMO) Scientific Committee on Immunotherapy and is
author/co-author of more than 170 scientific publications including
papers in Clinical Cancer Research, Cancer
Research, Blood, Nature Immunology, Nature Biotechnology, Lancet
Oncology, Immunology, Journal of Translational Medicine, PLOS
ONE and Oncoimmunology, among
others.
For more information, please contact:
Carlos de Sousa, CEO,
Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com
Michaela Gertz, CFO,
Immunicum
Telephone: +46 70 926 17 75
E-mail: ir@immunicum.com
Media Relations
Gretchen Schweitzer or Jacob
Verghese
Trophic Communications
Telephone: +49 89 2388 7735 or +49 172 861 8540
E-mail: ir@immunicum.com
About Immunicum AB (publ)
Immunicum is establishing a unique
immuno-oncology approach through the development of allogeneic,
off-the-shelf cell-based therapies. Our goal is to improve survival
outcomes and quality of life by priming the patient's own immune
system to fight cancer. The company's lead product ilixadencel,
consisting of pro-inflammatory allogeneic dendritic cells, has the
potential to become a backbone component of modern cancer
combination treatments in a variety of solid tumor indications.
Founded and based in Sweden, Immunicum is publicly traded on the
Nasdaq Stockholm. www.immunicum.com
20180917_Immunicum_SAB
Members_ENG_Final
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Immunicum AB via Globenewswire
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Apr 2024 to May 2024
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From May 2023 to May 2024